YILI(SH:600887) Jing Ji Guan Cha Wang·2025-05-21 11:21Group 1: Product Launch and Market Entry - Yili Group launched three new infant formula products in Hong Kong, including Jinlingguan Zhenhu Platinum, Jinlingguan Tofier Minyi, and Jinlingguan Tofier Minyi Initial [2] - The Jinlingguan Zhenhu Platinum infant formula is produced at Yili's "Yili Health Valley" facility in Hohhot, Inner Mongolia, which is recognized as a global benchmark for intelligent manufacturing in infant formula [2] - Yili has entered into a strategic partnership with Mannings, Hong Kong's largest health retail chain, to sell its products in over 200 Mannings stores and online [2][8] Group 2: Research and Development - Yili's Vice President Zhang Yipeng emphasized the company's commitment to quality, innovation, and internationalization, aiming to leverage Hong Kong as a global window for opportunities [4] - The "2025 Key Findings of Breast Milk Research" was released, showcasing 13 significant research outcomes, including the precise analysis of amino acid composition in Chinese breast milk [4][6] - Yili has obtained 28 invention patents in the HMO (Human Milk Oligosaccharides) field, enhancing its competitive edge in the nutrition and health sector [6] Group 3: Financial Performance and Market Expansion - In 2024, Yili achieved a total revenue of 115.78 billion yuan, with revenue from milk powder and dairy products reaching 29.675 billion yuan, marking a year-on-year growth of 7.53% [6] - The overseas business of infant formula experienced a remarkable growth of 68%, with Yili maintaining the top position in overall milk powder sales in the Chinese market [6]